Insider · CIK 0001547999
Maria C Freire
Files at BIIB (BIOGEN INC.), EXEL (EXELIXIS, INC.), ARE (ALEXANDRIA REAL ESTATE EQUITIES, INC.). First filing Feb 19, 2025, latest Feb 19, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EXEL: EXELIXIS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | EXELIXIS, INC. | $1.5M 44,114 shares | -33% | +38% from low-6% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2025 | BIIB BIOGEN INC. | AGrant or award Common Stock | +2,370 | $0.00 | $0 | 6,815 | Jun 18, 2025 |
| May 29, 2025 | EXEL EXELIXIS, INC. | AGrant or award Common Stock | +9,812 | $0.00 | $0 | 100,819 | May 30, 2025 |
| Feb 14, 2025 | EXEL EXELIXIS, INC. | MOption exercise Common Stock | +15,874 | $20.50 | $325k | 106,881 | Feb 19, 2025 |
| Feb 14, 2025 | EXEL EXELIXIS, INC. | MOption exercise Common Stock | +28,240 | $22.10 | $624k | 135,121 | Feb 19, 2025 |
| Feb 14, 2025 | EXEL EXELIXIS, INC. | SOpen-market sale Common Stock | -44,114 | $34.94 | $1.5M | 91,007 | Feb 19, 2025 |
| Feb 14, 2025 | EXEL EXELIXIS, INC. | MOption exercise Option (right to buy)derivative | -15,874 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | EXEL EXELIXIS, INC. | MOption exercise Option (right to buy)derivative | -28,240 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Jan 15, 2025 | ARE ALEXANDRIA REAL ESTATE EQUITIES, INC. | AGrant or award Common Stock | +2,032 | $0.00 | $0 | 7,453 | Jan 17, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.